Yang Jianling, Guo Zhengyang, Liu Xu, Liu Qi, Wu Meng, Yao Xueting, Liu Yang, Cui Cheng, Li Haiyan, Song Chunli, Liu Dongyang, Xue Lixiang
Center of Basic Medicine Research (CBMR), Peking University Third Hospital, Beijing, China.
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Front Pharmacol. 2020 Nov 20;11:574720. doi: 10.3389/fphar.2020.574720. eCollection 2020.
Chloroquine (CQ) and hydroxychloroquine (HCQ) have been challenged in treating COVID-19 patients and still under debate due to the uncertainty regarding the effectiveness and safety, and there is still lack of the systematic study on the toxicity of these two drugs. To further uncover the toxicity profile of CQ and HCQ in different tissues, we evaluated the cytotoxicity of them in eight cell lines and further adopted the physiologically based pharmacokinetic models to predict the tissue risk, respectively. Retina, myocardium, lung, liver, kidney, vascular endothelium, and intestinal epithelium originated cells were included in the toxicity evaluation of CQ and HCQ, respectively. The proliferation pattern was monitored in 0-72 h by IncuCyte S3. CC50 and the ratio of tissue trough concentrations to CC50 (R) were brought into predicted toxicity profiles. Compared to CQ, HCQ was found to be less toxic in six cell types except Hep3B and Vero cells. In addition, R was significantly higher in CQ treatment group compared to HCQ group, which indicates relative safety of HCQ. To further simulate the situation of the COVID-19 patients who suffered the dyspnea and hypoxemia, we also tested the cytotoxicity upon hypoxia and normoxia (1, 5 vs. 21% O). It was found that the cytotoxicity of CQ was more sensitive to hypoxia compared with that of HCQ, particularly in liver originated cells. Both CQ and HCQ showed cytotoxicity in time-dependent manner which indicates the necessity of short period administration clinically.
氯喹(CQ)和羟氯喹(HCQ)在治疗新冠肺炎患者方面受到了质疑,由于其有效性和安全性存在不确定性,目前仍在争论中,而且对于这两种药物的毒性仍缺乏系统性研究。为了进一步揭示CQ和HCQ在不同组织中的毒性特征,我们分别评估了它们在8种细胞系中的细胞毒性,并进一步采用基于生理的药代动力学模型来预测组织风险。视网膜、心肌、肺、肝、肾、血管内皮和肠上皮来源的细胞分别被纳入CQ和HCQ的毒性评估。通过IncuCyte S3在0至72小时监测增殖模式。将半数细胞毒性浓度(CC50)以及组织谷浓度与CC50的比值(R)纳入预测的毒性特征。与CQ相比,发现HCQ在除Hep3B和Vero细胞外的六种细胞类型中毒性较小。此外,CQ治疗组的R显著高于HCQ组,这表明HCQ具有相对安全性。为了进一步模拟新冠肺炎患者出现呼吸困难和低氧血症的情况,我们还测试了在缺氧和常氧(1%、5%与21%氧气)条件下的细胞毒性。结果发现,与HCQ相比,CQ的细胞毒性对缺氧更敏感,尤其是在肝来源的细胞中。CQ和HCQ均呈时间依赖性显示细胞毒性,这表明临床上需要短期给药。